Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017

Details for Mechanism ID: 17286
Country/Region: India
Year: 2016
Main Partner: Science Health Allied Research Education Foundation
Main Partner Program: India
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $1,200,000 Additional Pipeline Funding: $200,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $642,857
Treatment: Adult Treatment (HTXS) $557,143
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 6,230
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 5,185
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 158,757
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,990
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 19,654
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,748
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 39,472
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 62,864
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 69,215
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,714
TX_CURR Aggregated Age/Sex: <15 Male 2017 2,569
TX_CURR Aggregated Age/Sex: 15+ Female 2017 24,639
TX_CURR Aggregated Age/Sex: 15+ Male 2017 36,959
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 65,881
TX_CURR Sum of Aggregated Age/Sex <15 2017 4,283
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 61,598
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 65,881
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 224
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 337
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 3,224
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 4,836
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 8,621
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 8,621
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 168
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 251
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,407
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,610
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 6,436
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 8,410
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 220
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 329
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,145
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,716
Cross Cutting Budget Categories and Known Amounts Total: $50,000
Human Resources for Health $50,000